{
  "Variants Include": [
    {
      "Gene": "PARK2",
      "variants": [
        {
          "HGVS": "NM_000924.2:c.601G>A",
          "cDNA Change": {
            "transcript": "NM_000924.2",
            "ref": "G",
            "alt": "A",
            "position": "601"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "R",
            "position": "201"
          },
          "Description in input context": "c.601G>A (p.G201R)"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0005274"
  },
  "Experiment Method": [
    {
      "Assay Method": "Expression studies and functional assays",
      "Material used": {
        "Material Source": "Human brain tissue and cell lines",
        "Material Name": "Postmortem brain tissue, HEK293",
        "Description": "Studies conducted using postmortem brain tissue and HEK293 cells."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000924.2:c.601G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "loss-of-function",
          "Result Description": "The variant reduces Parkin ubiquitination activity, correlating with disease progression."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were performed."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each sample was analyzed in triplicate."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type PARK2 was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Empty vector was used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "Yes",
        "Counts": "2"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "Yes",
        "Counts": "1"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "ANOVA was used for statistical analysis."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Parkin ubiquitination activity greater than 80% in control samples.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Parkin ubiquitination activity less than 50% in mutant samples.",
        "Source": "Literature"
      },
      "Approved Assay": "Yes"
    },
    {
      "Assay Method": "Knockdown and overexpression experiments",
      "Material used": {
        "Material Source": "HEK293 cell lines",
        "Material Name": "HEK293",
        "Description": "Experiments conducted using HEK293 cells with siRNA knockdown and plasmid overexpression."
      },
      "Readout type": "Qualitative",
      "Readout description": [
        {
          "Variant": "NM_000924.2:c.601G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "loss-of-function",
          "Result Description": "Knockdown of PARK2 (p.G201R) led to increased alpha-synuclein aggregation, while overexpression reduced it."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were performed."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each experiment was repeated three times."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type PARK2 overexpression served as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Scrambled siRNA was used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "Yes",
        "Counts": "2"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "Yes",
        "Counts": "1"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "t-test was used for statistical analysis."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Alpha-synuclein aggregation levels below 20% in control cells.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Alpha-synuclein aggregation levels above 40% in mutant cells.",
        "Source": "Literature"
      },
      "Approved Assay": "Yes"
    },
    {
      "Assay Method": "Immunohistochemistry and biochemical assays",
      "Material used": {
        "Material Source": "Postmortem brain tissue",
        "Material Name": "Postmortem brain tissue from PD patients",
        "Description": "Immunohistochemistry and biochemical assays performed on postmortem brain tissue."
      },
      "Readout type": "Qualitative",
      "Readout description": [
        {
          "Variant": "NM_000924.2:c.601G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "loss-of-function",
          "Result Description": "Reduced Parkin immunoreactivity and increased Lewy body pathology in PD brains with the variant."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were performed."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each slide was analyzed in duplicate."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Normal brain tissue was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "No primary antibody was used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "Yes",
        "Counts": "2"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "Yes",
        "Counts": "1"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "Chi-square test was used for statistical analysis."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Parkin immunoreactivity above 50% in normal brain tissue.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Parkin immunoreactivity below 30% in PD brains with the variant.",
        "Source": "Literature"
      },
      "Approved Assay": "Yes"
    },
    {
      "Assay Method": "Cell viability assays and ubiquitination studies",
      "Material used": {
        "Material Source": "SH-SY5Y cell lines",
        "Material Name": "SH-SY5Y",
        "Description": "Cell viability assays and ubiquitination studies conducted on SH-SY5Y cells."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000924.2:c.601G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "loss-of-function",
          "Result Description": "The variant significantly reduced cell viability and impaired ubiquitination of target proteins."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were performed."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each experiment was repeated three times."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type PARK2 overexpression served as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Empty vector was used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "Yes",
        "Counts": "2"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "Yes",
        "Counts": "1"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "ANOVA was used for statistical analysis."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Cell viability above 80% in control cells.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Cell viability below 50% in mutant cells.",
        "Source": "Literature"
      },
      "Approved Assay": "Yes"
    },
    {
      "Assay Method": "Molecular dynamics simulations and co-immunoprecipitation experiments",
      "Material used": {
        "Material Source": "HEK293 and SH-SY5Y cell lines",
        "Material Name": "HEK293, SH-SY5Y",
        "Description": "Molecular dynamics simulations and co-immunoprecipitation experiments conducted on HEK293 and SH-SY5Y cells."
      },
      "Readout type": "Qualitative",
      "Readout description": [
        {
          "Variant": "NM_000924.2:c.601G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "loss-of-function",
          "Result Description": "The variant disrupts Parkin's interaction with ubiquitin ligase substrates, confirmed via co-immunoprecipitation."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were performed."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each experiment was repeated three times."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type PARK2 was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Empty vector was used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "Yes",
        "Counts": "2"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "Yes",
        "Counts": "1"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "t-test was used for statistical analysis."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Ubiquitin ligase interaction above 70% in control cells.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Ubiquitin ligase interaction below 30% in mutant cells.",
        "Source": "Literature"
      },
      "Approved Assay": "Yes"
    }
  ]
}